TFAP2A and familial pancreatic carcinoma: Targetting AP-2 factors could as well lead to drug resistance, as confirmed in pancreatic cancer, where gemcitabine resistance is obtained via TFAP2C suppression by miR-10a-5p [78], or in bladder cancer where TFAP2A is suppressed by miR-193a-5p [79].